F. Leal da Costa

Fernando Leal da Costa is an Invited Associate Professor in the area of Management of Health Organizations and Services at NOVA NSPH. His areas of interest are health technology assessment and clinical governance, with particular emphasis on clinical safety.

He was the first National Coordinator for Oncology and represented Portugal on the Public Health Steering Committee of the Council of Europe. In addition to his academic role, he is a Senior Hematology Assistant at IPO Lisbon, where he is also responsible for the Myeloma Clinic. His professional activity has focused on the diagnosis and treatment of hematological and oncological diseases, with a special focus on myeloma, high-dose chemotherapy and hematopoietic cell transplantation.

He previously held the position of Director of the Hematology Service and the Bone Marrow Transplantation Unit (BMTU), and head of the Intensive Hematological Care Unit, which was later merged with the BMTU. He also served as Chairman of the IPO de Lisbon Research Council and Ethics Committee, and was a member of the Pharmacy and Therapeutics Committee. He is currently a member of INFARMED's Medicines Evaluation Commission.

He was Assistant Secretary of State to the Minister of Health from 2011 to 2015, the year in which he became Minister of Health in the 20th Constitutional Government.

Graduated in Medicine from the Faculty of Medicine of the University of Lisbon.

PEDAGOGICAL COORDINATION AND PARTICIPATION IN TEACHING

• Clinical Governance
• Organization and Management of Health Services
• Collaboration in the Specialization Course in Hospital Administration and in the Master's Degree in Health Management with classes on clinical management topics

He has worked mainly on clinical trials in the field of Myeloma.

• Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. | A. Palumbo, F. Davies, M. Kropff , J. Bladé, M. Delforge, F. Leal da Costa, R. Garcia Sanz, S. Schey, T. Facon, G. Morgan e P. Moreau. Ann Hematol, DOI 10.1007/s00277-010-0925-1(epub Mar 16)
• Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. |Heinz Ludwig, Meral Beksac, Joan Bladé, Jamie  Cavenagh, Michele Cavo, Michel Delforge, Meletios Dimopoulos, Johannes Drach, Hermann Einsele, Thierry Facon, Harmut Goldschimidt, jean-Luc Harou sseau, Urs Hess, Martin Kropff, Fernando Leal da Costa, Vernon Louw, Hila Magen-Nativ, larisa Mendeleeva, Hareth Nahi, Torben Plesner, Jesús San-Miguel Pietre Sonneveld, Miklos Udvardy, Pia Sondergeld, Antonio Palumbo | The Oncologist 2011;16:388–403.
• A Crise e Desigualdades em Saúde | F. Leal da Costa |A NOVA Saúde Pública – A Saúde Pública na Era do Conhecimento, Gradiva, 2011: 151-155.
• Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) |Antonio Palumbo, Sara Bringhen, Heinz Ludwig, Meletios A. Dimopoulos, Joan Bladé, Maria V. Mateos, Laura Rosiñol, Mario Boccadoro, Michele Cavo, Henk Lokhorst, Sonja Zweegman, Evangelos Terpos, Faith Davies, Cristophe Driessen, Peter Gimsing, Martin Gramatzki, Roman Hàjek, Hans E. Johnsen, Fernando Leal da Costa, Orhan Sezer, Andrew Spencer, Meral Beksac, Gareth Morgan, Hermann Einsele, Jesus F. San Miguel, Pietre Sonneveld | Blood. 2011;118(17):4519-4529
• The portuguese healthcare system: Universal and comprehensive | Paulo Boto e Fernando Leal da Costa | (E) Hospital 2012;(3):36-39.
• Melhor Saúde para um Estado Melhor | Fernando Leal da Costa | Revista Portuguesa de Gestão de Saúde 2014;(13):6-9.
• Políticas e Impactos para o Doente Oncológico | Fernando Leal da Costa | Revista Portuguesa de Gestão de Saúde 2015;(17):20-33.
• Role of 18F-FDG Positron Emission Tomography/Computed Tomography in the diagnosis and management of multiple myeloma and other plasma cell dyscrasias: a consensus statement by the International Myeloma Working Group | Michele Cavo, Evangelos Terpos, Cristina Nanni, Philippe Moreau, Suzanne Lentzsch, Sonja Zweegman, Jens Hillengass, Monika Engelhardt, Saad Z. Usmani, David H. Vesole, Jesus San Miguel, Shaji K. Kumar, Paul G. Richardson, Joseph R. Mikhael, Fernando Leal da Costa, Meletios-Athanassios Dimopoulos, Chiara Zingaretti, Niels Abilgaard, Hartmut Goldschmidt, Robert Orlowski, Chng Wee Joo, Hermann Einsele, Sagar Lonial, Bart Barlogie, Kenneth C. Anderson, S. Vincent Rajkumar, Brian G.M. Durie and Elena Zamagni | The Lancet Oncology 2017;18(4): e206–e217.

NOVA RESEARCH PORTAL:   https://novaresearch.unl.pt/en/persons/fernando-leal-da-costa

He was Deputy Director-General of Health, Consultant for Health Policy Affairs at the President of the Republic's Civil House, National Coordinator for Oncology, Assistant Secretary of State to the Minister of Health and Minister of Health.